DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/18/2023* 10:00 EST Earnings Call Q2 2023 -- -- --
05/05/2023* -- Results Q1 2023 -- -- --
08/18/2022 -- Results Q2 2022 -- -- --
08/18/2022 10:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -- -- --
03/10/2022 -- Results Q4 2021 -- -- --
03/10/2022 10:00 EST Earnings Call Q4 2021 -- -- --
11/01/2021 -- Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 05/05/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date 08/18/2022
Beat/Miss Upgrade
Return Since -11.28%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe.
URL http://www.addextherapeutics.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 05, 2023 (est.)
Last Earnings Release Aug. 18, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
--
--
--
--
--
-53.06%
-89.98%
87.27%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
2.96%
--
-1.39%
-26.17%
-9.84%
-39.32%
-4.26%
-58.79%
6.86%
--
15.89%
21.68%
113.2%
151.4%
-50.51%
-46.36%
7.11%
--
--
29.71%
-69.83%
-45.55%
-4.33%
-92.71%
-29.79%
--
--
--
--
--
--
16.22%
4.65%
As of March 22, 2023.

Profile

Edit
Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe.
URL http://www.addextherapeutics.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 05, 2023 (est.)
Last Earnings Release Aug. 18, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ADXN Tweets